Lundbeck's Rexulti has failed to achieve the primary endpoint of two Phase III bipolar disorder studies.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.